Cerliponase alfa ▼ is not registered in all countries, and where it is registered the content of its indication along with other content may vary.
Please refer to your local prescribing information before prescribing cerliponase alfa.
▼ This medicinal product is subject to additional monitoring, special reporting is required in relation to adverse reactions. Email us at medinfo@bmrn.com for further details.
Explore upcoming educational webinars, expert panels, scientific meetings and events dedicated to CLN2 disease. Stay connected to the latest discussions and insights shaping the future of CLN2 care.
Don’t miss the next opportunity to connect with CLN2 experts and peers- register now to join upcoming events.
On Demand
During this webinar, first broadcast at the BioMarin sponsored CLN2 Masterclass 2021, Professor Stéphane Auvin from the Robert Debré University Hospital & Université de Paris, Paris, France, focusses on treatable infantile epilepsy (with a particular focus about myoclonic epilepsies), how to identify them and how to diagnose as early as possible.
Event Recording Available
On Demand
Prof Schulz reviews the challenges and benefits of long-term treatment with cerliponase alfa, management of atypical CLN2 phenotypes, and the role of newborn screening in achieving early, ideally pre-symptomatic intervention in CLN2 disease.
Event Recording Available
On Demand
Dr Ram explains the importance of early recognition of CLN2 disease – its key signs and symptoms, how best to support the diagnostic journey, and the benefits of early intervention on patient outcomes.
Event Recording Available
On Demand
Welcome to this inaugural LYNK webinar with Professor Angela Schulz and an esteemed global faculty to discuss transitioning patients with CLN2 disease from paediatric to adolescent care, with practical guidance on meeting the evolving needs of patients and working effectively with caregivers and care teams to navigate the process.
Event Recording Available